HKSE - Delayed Quote • HKD
Simcere Pharmaceutical Group Limited (2096.HK)
At close: April 26 at 4:08 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,607,805.000
6,607,805.000
6,324,082.000
4,999,718.000
4,508,720.000
Cost of Revenue
1,623,652.000
1,623,652.000
1,327,404.000
1,079,983.000
899,927.000
Gross Profit
4,984,153.000
4,984,153.000
4,996,678.000
3,919,735.000
3,608,793.000
Operating Expense
4,257,652.000
4,257,652.000
4,422,047.000
3,687,923.000
3,018,910.000
Operating Income
726,501.000
726,501.000
574,631.000
231,812.000
589,883.000
Net Non Operating Interest Income Expense
20,392.000
20,392.000
25,459.000
-2,561.000
-107,481.000
Pretax Income
740,038.000
740,038.000
886,254.000
1,401,797.000
805,088.000
Tax Provision
26,088.000
26,088.000
-40,478.000
-97,124.000
140,801.000
Net Income Common Stockholders
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
Diluted NI Available to Com Stockholders
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
Basic EPS
1.21
0.27
0.36
0.58
0.26
Diluted EPS
1.20
0.27
0.36
0.58
0.26
Basic Average Shares
2,616,325.532
2,608,533.908
2,611,171.592
2,608,641.618
2,608,641.618
Diluted Average Shares
2,626,069.498
2,608,533.908
2,620,375.892
2,611,357.884
2,608,641.618
Total Operating Income as Reported
711,802.000
711,802.000
860,605.000
1,448,544.000
926,836.000
Total Expenses
5,881,304.000
5,881,304.000
5,749,451.000
4,767,906.000
3,918,837.000
Net Income from Continuing & Discontinued Operation
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
Normalized Income
721,018.354
721,018.354
686,779.750
930,408.250
361,642.164
Interest Income
54,960.000
54,960.000
59,867.000
68,287.000
26,248.000
Interest Expense
34,568.000
34,568.000
34,408.000
70,848.000
133,729.000
Net Interest Income
20,392.000
20,392.000
25,459.000
-2,561.000
-107,481.000
EBIT
774,606.000
774,606.000
920,662.000
1,472,645.000
938,817.000
EBITDA
1,084,200.000
1,084,200.000
1,204,309.000
1,724,452.000
1,161,146.000
Reconciled Cost of Revenue
1,623,652.000
1,623,652.000
1,327,404.000
1,079,983.000
899,927.000
Reconciled Depreciation
309,594.000
309,594.000
283,647.000
251,807.000
222,329.000
Net Income from Continuing Operation Net Minority Interest
714,761.000
714,761.000
930,868.000
1,507,096.000
669,534.000
Total Unusual Items Excluding Goodwill
-6,486.000
-6,486.000
325,451.000
768,917.000
373,152.000
Total Unusual Items
-6,486.000
-6,486.000
325,451.000
768,917.000
373,152.000
Normalized EBITDA
1,090,686.000
1,090,686.000
878,858.000
955,535.000
787,994.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-228.646
-228.646
81,362.750
192,229.250
65,260.164
12/31/2020 - 10/27/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade